Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.61 |
| ▸ | PDE5A | O76074 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868103 | 0.83 | PDE5A (0.82) | GBA1PDE5AKDM4EMAPK1SLC6A3 | |
| SCHEMBL4237965 | 0.81 | GBA1 (0.62) | GBA1PDE5AKDM4EMAPK1MEN1 | |
| SCHEMBL4868215 | 0.81 | PDE5A (0.82) | GBA1PDE5AKDM4EMAPK1SLC6A3 | |
| SCHEMBL3536885 | 0.80 | PDE5A (0.49) | PDE5ACYP3A4 | |
| SCHEMBL3536886 | 0.80 | PDE5A (0.49) | PDE5ACYP3A4 | |
| SCHEMBL28805458 | 0.78 | PDE5A (0.76) | GBA1PDE5AMAPK1MEN1KMT2A | |
| SCHEMBL4867641 | 0.78 | PDE5A (0.78) | GBA1PDE5AKDM4EMAPK1SLC6A3 | |
| SCHEMBL6671471 | 0.77 | SLC2A1 (0.70) | PDE5AKDM4EMAPK1MEN1KMT2A | |
| SCHEMBL1085431 | 0.76 | PDE5A (1.00) | GBA1PDE5AKDM4EMAPK1SLC6A3 | |
| SCHEMBL18354082 | 0.76 | GBA1 (1.00) | GBA1PDE5AKDM4EMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547702-B2 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2004030672-A1 | USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| EP-1318984-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024667-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | SERPINA3, APOL1, MGAT3 | GBA1 52/4885PDE5A 2783/4885KDM4E 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.